Three things to know:
1. Bioventus’ Durolane and Gelsyn-3 treatments for knee osteoarthritis pain will be made available to UnitedHealth commercial plan members starting Oct. 1.
2. Durolane is a single-injection and Gelsyn-3 is a three-injection hyaluronic acid-based joint fluid treatment.
3. Bioventus plans to expand Durolane into Australia and New Zealand and is launching Durolane SJ — another HA-based product — in both countries later this year.
More articles on devices:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
